Abaxis receives CLIA waiver for cpillary sampling for cholesterol, HDL Abaxis announced the Food and Drug Administration granted CLIA waived status for capillary draw for CHOL, HDL and TRIG. Combined with existing CLIA waived tests for liver diagnostics using capillary samples, Abaxis now has two complete Lipid Panels which can be used by healthcare professionals to diagnose, treat and monitor hyperlipidemia patients using a sample obtained from either venous blood or a capillary draw. Obtaining CLIA waived status for capillary sampling is an important step in bringing comprehensive care closer to the patients in the U.S.
News For ABAX From The Last 14 Days
Check below for free stories on ABAX the last two weeks.